Ari VanderWalde

Watermill Ventures is a private equity firm founded by Steven E. Karol in 2004,headquarters in US.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Oncology Development Partners LLC is an American company that focuses on research and development in the field of oncology.

United BioSource Corp. is a scientific and medical affairs organization that partners with life science companies to develop and commercialize their products. The company is involved in pre- and post-approval product development; pricing, coverage, reimbursement, and access strategies; and medical publication and communications. United BioSource Corp. was founded by Ethan D. Leder and Mark P. Cleinin in 2003 and is headquartered in Chevy Chase, MD.

Bain & Co., Inc. provides management consulting services. It offers advisory services to the companies on their critical issues and opportunities: strategy, marketing, organization, operations, technology and mergers and acquisitions, across all industries and geographies. The company was founded in 1973 and is headquartered in Boston, MA.

Vermont Academy operates as a school. The firm’s courses include advanced physics, environmental science, advanced biology, biochemistry and more. The company was founded in 1872 and is headquartered in Saxtons River, VT.

Autem Therapeutics is a privately held bioelectric and oncology therapeutic company based in Hanover, NH, USA. The company is developing a non-invasive and non-toxic oncology treatment platform targeting liver cancer and other solid tumor cancers. Autemsys™ therapy, the company's breakthrough treatment, delivers personalized, amplitude-modulated electromagnetic frequencies that show promise in shrinking cancerous tumors, enhancing quality of life, and extending survival in early and advanced stage cancer patient populations. The company has received FDA breakthrough designation for its Autemsys™ therapy for the treatment of advanced HCC patients. Autem Therapeutics anticipates submitting an FDA investigational device exemption (IDE) to initiate FDA pivotal clinical trials in late 2022 or early 2023. The company was founded by Frederico Costa and Michael A. Choukas, and Michael A. Choukas has been the CEO since incorporation.